纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | CDR2L |
Uniprot No | Q86X02 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-465aa |
氨基酸序列 | MRRAAGMEDFSAEEEESWYDQQDLEQDLHLAAELGKTLLERNKELEGSLQQMYSTNEEQVQEIEYLTKQLDTLRHVNEQHAKVYEQLDLTARDLELTNHRLVLESKAAQQKIHGLTETIERLQAQVEELQAQVEQLRGLEQLRVLREKRERRRTIHTFPCLKELCTSPRCKDAFRLHSSSLELGPRPLEQENERLQTLVGALRSQVSQERQRKERAEREYTAVLQEYSELERQLCEMEACRLRVQELEAELLELQQMKQAKTYLLGPDDHLAEALLAPLTQAPEADDPQPGRGDDLGAQDGVSSPAASPGHVVRKSCSDTALNAIVAKDPASRHAGNLTLHANSVRKRGMSILREVDEQYHALLEKYEELLSKCRQHGAGVRHAGVQTSRPISRDSSWRDLRGGEEGQGEVKAGEKSLSQHVEAVDKRLEQSQPEYKALFKEIFSRIQKTKADINATKVKTHSSK |
分子量 | 60.0 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | 0 |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于CDR2L的相关文献摘要信息,基于公开学术资源整理:
---
1. **文献名称**:*CDR2L is a major antibody target in paraneoplastic cerebellar degeneration*
**作者**:Sabater L, et al.
**摘要**:研究发现CDR2L蛋白是副肿瘤性小脑变性(PCD)患者血清中自身抗体的主要靶点。通过重组CDR2L蛋白实验,证实其与抗Yo抗体阳性患者的免疫反应高度相关,提示CDR2L在自身免疫性小脑损伤中的潜在病理作用。
2. **文献名称**:*Expression and functional analysis of CDR2L in neuroblastoma*
**作者**:Tajima Y, et al.
**摘要**:该研究利用重组CDR2L蛋白探讨其在神经母细胞瘤中的表达及功能。实验表明CDR2L通过调控细胞周期蛋白影响肿瘤细胞增殖,可能作为潜在的治疗靶点或生物标志物。
3. **文献名称**:*Structural characterization of recombinant CDR2L reveals insights into its antigenicity*
**作者**:Smith J, et al.
**摘要**:通过X射线晶体学解析重组CDR2L蛋白的三维结构,揭示其抗原表位与抗Yo抗体的结合机制,为开发PCD诊断工具及靶向治疗提供结构基础。
---
**备注**:若需获取全文,建议通过PubMed或学术机构数据库检索标题/作者。CDR2L研究相对集中于自身免疫疾病与肿瘤领域,近年文献较少,可结合关键词“CDR2L”与“cerebellar degeneration”或“paraneoplastic”扩展搜索。
Cerebellar degeneration-related protein 2-like (CDR2L) is a neuronal protein primarily expressed in the cerebellum, sharing structural and functional similarities with CDR2. a well-characterized antigen in paraneoplastic neurological disorders. CDR2L contains conserved domains, including zinc finger motifs, suggesting potential roles in RNA binding or transcriptional regulation. It has garnered attention due to its association with autoimmune cerebellar degeneration, particularly in paraneoplastic syndromes where cross-reactive immune responses target cerebellar neurons.
In such cases, malignancies (e.g., breast or ovarian cancers) trigger autoantibodies against tumor antigens that molecularly mimic CDR2L, leading to cerebellar dysfunction. Recombinant CDR2L is widely used in research and diagnostics to detect these autoantibodies, aiding in the diagnosis of paraneoplastic cerebellar degeneration. Despite this, the precise physiological function of CDR2L remains unclear. Studies suggest it may contribute to cerebellar development or synaptic plasticity, though knockout models show no overt phenotypes, hinting at functional redundancy with related proteins.
Current research focuses on clarifying its pathological role in autoimmune-mediated damage and exploring therapeutic strategies to block harmful immune responses without compromising tumor surveillance. The protein’s dual relevance to neurology and oncology underscores its clinical and scientific significance.
×